(Q36979534)

English

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

scientific article published on 23 January 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

11

object named as

Karen Dybkær

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

object named as

Jane N Winter

26

0 references

Ganiraju Manyam

object named as

Ganiraju C Manyam

4

0 references

Santiago Montes-Moreno

object named as

Santiago Montes-Moreno

10

0 references

Roberto N. Miranda

object named as

Roberto N Miranda

8

0 references

Michael Boe Møller

object named as

Michael B Møller

29

0 references

object named as

Govind Bhagat

15

0 references

Miguel A. Piris

object named as

Miguel A Piris

30

0 references

32

object named as

Ronald S Go

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kristy L Richards

16

object named as

Kristy L Richards

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Han van Krieken

19

object named as

J Han van Krieken

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Zijun Y Xu-Monette

2

object named as

Zijun Y Xu-Monette

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

12

object named as

April Chiu

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

17

object named as

Eric D Hsi

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

William W L Choi

18

object named as

William W L Choi

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Maurilio Ponzoni

23

object named as

Maurilio Ponzoni

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Andrés J M Ferreri

24

object named as

Andrés J M Ferreri

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

35

object named as

Ken H Young

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

13

object named as

Attilio Orazi

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Alexander Tzankov

6

object named as

Alexander Tzankov

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Aarthi Balasubramanyam

3

object named as

Aarthi Balasubramanyam

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Shimin Hu

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Carlo Visco

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Wei-min Liu

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Li Zhang

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Youli Zu

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Qin Huang

20

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Jooryung Huh

21

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Weiyun Ai

22

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Xiaoying Zhao

25

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Mingzhi Zhang

27

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Ling Li

28

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yong Li

31

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Lin Wu

33

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

L Jeffrey Medeiros

34

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

23 January 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

121

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2715-2724

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Anaplastic large-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Double-hit B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Anaplastic Large Cell Lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

ALK+ lymphoma: clinico-pathological findings and outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Relation of CD30 expression to survival and morphology in large cell B cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

29 September 2017

CD30+ lymphoproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

27 June 2018

Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

27 June 2018

Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

27 June 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3700465

4 September 2018

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23343832

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2012-10-461848

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36979534&oldid=2112007737"